Clinical Data

In a randomized, double blind, parallel group, placebo controlled trial, SALCITAL (500 mg/day for a period of 6 weeks) along with therapeutic lifestyle changes treated group showed significant reduction in low density lipoprotein cholesterol (LDL-C) and fasting blood sugar (FBS) levels when compared to placebo in patients with prediabetes and mild to moderate hyperlipidemia.

Clinical study published in Journal of Medicinal Food (Korean Society of Food Science and Nutrition) 2013 Jun;16(6):564-8. doi: 10.1089/jmf.2013.2751.

Effect of SALCITAL on LDL-C and FBS levels

Safety data

SALCITAL (500 mg/day) showed no adverse effects in patients with prediabetes and mild to moderate hyperlipidemia throughout the study duration. The physical examination and clinical laboratory investigations performed on day 0 and week 6 in SALCITAL treated groups were found to be within normal limits.

* Disclaimer: “These statements have not been evaluated by the Food and Drug Administration or any other regulatory body. This product is not intended to diagnose, treat, cure or prevent any disease”.